KPV Integrative Peptides, also known as α-MSH(11–13) C-terminal tripeptides, are the core functional fragments derived from melanocyte-stimulating hormone α-MSH. Known for its "strong anti-inflammatory, mild antibacterial, low-irritant, and easily compatible" properties, it has been repeatedly validated in studies on inflammation and barrier repair in skin and mucous membranes, and is also found in some topical functional formulations and medical skincare applications.
As peptide research accelerates, demand for reliable raw materials has surged. Shaanxi Medibridge, a fully integrated manufacturer-trader with more than 14 years in the field, supplies high-purity short peptides at 99% or higher. Our KPV, for example, is no less than 99.58% pure, comfortably above the typical 95%+ industry benchmark. We deliver stable quality, responsive lead times, and documentation to support development from lab evaluation through scale-up and production.
COA
|
|
||
|
Product Name |
CAS Number |
Batch Number |
|
KPV Peptide |
67727-97-3 |
MB2510231852 |
|
Manufacturer Date |
Analysis Date |
Expiry Date |
|
2025-10-23 |
2025-10-24 |
2027-10-22 |
|
Sample Qty Base |
Packing |
Test Method |
|
450.52 GS |
10GS/BOTTLE |
HPLC |
|
Item |
Standard |
Results |
|
Purity |
≥98% |
99.56% |
|
Peptide Assay |
≥80% |
83.29% |
|
Mass Spectrum |
342.43 |
342.43 |
|
Solubility |
Soluble in water |
Complies |
|
Clarity and color of solution |
Clear and colorless |
Complies |
|
Sodium salt |
<5.0% |
1.72% |
|
Water |
≤7.0% |
3.16% |
|
Residual Solvent: |
||
|
Methanol |
≤0.3% |
Complies |
|
Isopropanol |
≤0.5% |
Complies |
|
Acetonitrile |
≤0.041% |
0.005% |
|
Methylene Chloride |
≤0.06% |
0.019% |
|
N,N-Dimethylformamide |
≤0.075% |
Complies |
|
Triethylamine |
≤0.029% |
Complies |
|
Tert-butyl methyl ether |
≤0.5% |
0.183% |
|
Endotoxin |
≤0.5 EU/mg |
Complies |
|
Microbial Limit |
Total aerobic bacteria <100 CFU/g Total yeast & mold <50 CFU/g |
<50 CFU/g <10 CFU/g |
|
Storage |
Keep in dark and cool dry place (-20 to 8°C) |
|
|
Conclusion |
The batch conforms to the IN-HOUSE standard |
|
|
|
||
Specification(for research use only)
Our advantages
1.KPV purity ≥99.58% (RP‑HPLC/LC‑MS), above the ≥95% norm.
2.14+ years, integrated manufacturing and QC.
3.Consistent lots; full COA and MS identity.
4.Scalable supply: mg to multi‑kg; short lead times.
5.Custom options: N‑Ac, C‑Am, salts; aliquots.
6.Lyophilized, amber vials; cold‑chain shipping; technical support.
|
Form |
Sample Order |
Specification |
|
Raw powder |
1 g |
Purity is NLT 99.58% |
|
Vials |
10 vials |
3ml/5ml/7ml/15ml vials etc. |
Operating Mechanism of KPV
Cell Entry and Receptor Dependence
In epithelial cells such as intestinal epithelium, KPV Integrative Peptides can be taken up into the cell via the oligopeptide transporter PepT1. When PepT1 is inhibited/knocked down, its anti-inflammatory effect is significantly weakened, suggesting that "intracellular access" is crucial for its activity.
In keratinocytes and fibroblasts, no stable dependence on the classical melanocortin axis like MC1R was observed; even in the absence of MC1R or under the condition of adding antagonists, it can still inhibit inflammatory readout, indicating that its main mechanism is receptor-independent/low-dependent.
Inhibition of the Inflammatory Signaling Axis
NF-κB Pathway: In TNF-α, IL-1β, or LPS stimulation models, KPV can reduce aberrant phosphorylation of IKK/IκBα, inhibit p65 subunit nuclear translocation, and subsequently downregulate multiple NF-κB target genes (such as IL-6, IL-8/CXCL8, TNF, PTGS2/COX-2, NOS2/iNOS). At the protein level, this manifests as decreased expression of COX-2 and iNOS; at the secretory level, it manifests as a significant reduction in inflammatory cytokines and chemokines.
MAPK Pathway: In multiple cell lines, p38 and JNK phosphorylation levels are suppressed, while the effect on ERK varies depending on the model. Inhibition of this axis and NF-κB downregulation are additive, amplifying the overall inhibitory effect on the pro-inflammatory transcriptional network.
Second messenger level: This product is not stable in enhancing cAMP, nor does it form a sustained activation of PKA/CREB, which is different from the classic mode of α-MSH ontology via MC1R-cAMP-PKA, further supporting its "atypical melanocortin-like" characteristics.
Barrier Homeostasis and Tight Junction Protection
In an epithelial/keratinocyte monolayer model, KPV increases transepithelial electrical resistance (TEER) and reduces bypass permeability of FITC-labeled probes; immunofluorescence shows that the continuity and abundance of ZO-1 (TJP1), Occludin (OCLN), and some Claudin at their online junctions are maintained or restored.Against the backdrop of inflammatory stimulation-induced degradation and relocation of tight junction proteins, KPV reduces stress activation and cytoskeletal disorder of associated kinases, thereby preserving the membrane anchoring and barrier function of the junctional complex. This barrier effect is mutually reinforcing with anti-inflammatory transcriptional repression.
Innate Immunity and Cell Interactions
Neurocytic Axis: In vivo stimulation (such as TPA ear swelling, UV/chemical stimulation), this product reduces myeloperoxidase (MPO) activity and neutrophil infiltration, resulting in a decrease in histological inflammation scores; this is consistent with its downregulation of chemokines such as IL-8.Macrophages/Dendritic Cells: Against the backdrop of Toll-like receptor activation such as LPS, KPV inhibits the release of TNF-α and IL-1β, reducing paracrine proliferation; a shift towards a low-inflammatory phenotype was observed in some models, but this shift is cell line and microenvironment dependent.
FAQ
Q: What is KPV?
A: KPV is the synthetic tripeptide Lys‑Pro‑Val (H‑K‑P‑V‑OH; MW ≈342.44 g/mol).
Q: What is the purity and how is it confirmed?
A: A: Our KPV is ≥99.58% pure by RP‑HPLC with LC‑MS identity confirmation and a full COA.
Q: How is it supplied and stored?
A: Lyophilized powder in amber vials; store desiccated at −20°C, protected from light.
Q: How do I reconstitute it?
A: Dissolve in BAC water or PBS (or 0.1%–1% acetic acid if needed), then aliquot and freeze.
Q: Is it sterile and what about endotoxin?
A: Research‑use only; not sterile unless ordered sterile‑filtered, with endotoxin testing available on request.
Q: Do you offer custom options or scale‑up?
A: Yes-N‑acetylation, C‑amidation, salt forms, aliquoting, and production from mg to multi‑kg.
Q: How is it shipped?
A: Stable for routine transit; freeze on receipt.
Q: Is Shaanxi Medibridge a manufacturer of peptides for scientific research?
A: Yes, we are a fully integrated manufacturer-trader with more than 14 years in the field.
Shaanxi Medibridge is a dedicated peptide manufacturer serving universities and labs worldwide. We offer lyophilized KPV Integrative Peptides for research use, guaranteed purity ≥99.72%. Expect reliable lead times, careful packaging, prompt technical support, and consistent in‑stock availability. Worldwide delivery. For quotes or samples: hi@medibridgeapi.com or WhatsApp +44 07548632075.
Hot Tags: kpv integrative peptides, China kpv integrative peptides manufacturers, suppliers, factory, BPC 157 Powder, Survodutide Peptide, Ghrp Peptide, Selank Powder, Peptide SS 31, Thymosin Alpha 1 Peptide
